Shares of Adaptive Biotechnologies Corp (ADPT) jumped 5.03% in Thursday's pre-market trading session after the company reported better-than-expected full year 2024 earnings results. The biotech firm's earnings per share surpassed analyst estimates by 3.2%, despite posting a net loss for the year.
ADPT's full year 2024 revenue grew 5.1% year-over-year to $179 million, in line with estimates. While the company remained unprofitable with a net loss of $159.5 million, the loss narrowed by 29% compared to the previous year, indicating improving financial performance.
Looking ahead, analysts forecast ADPT's revenue to grow at an impressive 18% annualized rate over the next three years, outpacing the 6% growth projected for the broader life sciences industry. However, the company still faces some risks, with two warning signs identified by analysts.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。